Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

The Chikungunya virus has been in the news lately as individuals who took the vaccine to prevent it were hospitalized. Many ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

The MHRA is working with the manufacturer of the IXCHIQ  vaccine, Valneva. This vaccine was approved by the MHRA in February 2025. There will be no impact on operational issues as this vaccine is not ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Thanks to a clever modification of the baculovirus, vaccines can now be produced in insect cells more easily and cleaner.

This is a precautionary measure while the MHRA conducts the safety review. Following global reports of serious adverse events ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

Chikungunya is a mosquito-borne viral disease caused by the Chikungunya Virus (CHIKV) and is transmitted by infected female ...